Clinical Trial Update: Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and anti-inflammatory effects of SB681323 in patients with chronic obstructive pulmonary disease (COPD) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SB681323

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED